Navigation Links
Indevus Pharmaceuticals Announces Release of 2008 Annual Report
Date:1/27/2009

LEXINGTON, Mass., Jan. 27 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) today announced that a copy of its 2008 Annual Report has been posted on and is available at the Company's website at www.indevus.com. In addition, the Company's stockholders may obtain a free hard copy of the Annual Report by contacting the Company's Investor Relations department at (781) 861-8444 or by mailing written requests to Indevus Pharmaceuticals, Inc., Attention Investor Relations, 33 Hayden Ave., Lexington, Massachusetts 02421.

The Company's common stock is listed and traded on the NASDAQ Global Market under the symbol "IDEV."

About Indevus Pharmaceuticals

Indevus Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the acquisition, development, and commercialization of products to treat conditions in urology and endocrinology. The Company's approved products include SANCTURA(R) and SANCTURA XR(TM) for overactive bladder, VANTAS(R) for advanced prostate cancer, SUPPRELIN(R) LA for central precocious puberty, and DELATESTRYL(R) to treat male hypogonadism. The Indevus development pipeline contains multiple compounds within the Company's core therapeutic areas in addition to several partnered or partnerable programs. The most advanced compounds in development include, VALSTAR(TM) for bladder cancer, NEBIDO(R) for hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering.

    Contact:
    Michael W. Rogers
    EVP and Chief Financial Officer
    (781) 861-8444

    Robin L. DeCarlo
    Sr. Director, Corporate Communications
    (781) 402-3405


'/>"/>
SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results
2. Indevus Pharmaceuticals to Present at Upcoming Investor Conferences
3. Indevus and FDA Agree on Path Forward for NEBIDO(R)
4. Indevus Announces Private Placement of $105 Million of Non-Recourse Notes
5. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
6. Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2008 Financial Results on August 5, 2008
7. Indevus Receives Approvable Letter from FDA for NEBIDO(R)
8. Indevus Announces Management Changes
9. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
10. 125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative
11. Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Global demand ... 4.6 percent through 2020 to $7.2 billion.  This ... and beverages, cleaning products, biofuel production, animal feed, ... biotechnology, diagnostics, and biocatalysts). Food and beverages will ... driven by increasing consumption of products containing enzymes ...
(Date:6/27/2016)... ... 2016 , ... Newly created 4Sight Medical Solutions ... healthcare market. The company's primary focus is on new product introductions, to include ... are necessary to help companies efficiently bring their products to market. , The ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
Breaking Biology Technology:
(Date:5/24/2016)... facilitates superior patient care by providing unparalleled technology to leaders of the medical imaging ... product recently added to the range of products distributed by Ampronix. Photo ... ... ... News ...
(Date:5/16/2016)... 16, 2016   EyeLock LLC , a market ... opening of an IoT Center of Excellence in ... the development of embedded iris biometric applications. ... convenience and security with unmatched biometric accuracy, making it ... from DNA. EyeLock,s platform uses video technology to deliver ...
(Date:5/9/2016)... , UAE, May 9, 2016 ... it comes to expanding freedom for high net worth ... Even in today,s globally connected world, there is still ... system could ever duplicate sealing your deal with a ... second passports by taking advantage of citizenship via investment ...
Breaking Biology News(10 mins):